FDA panel backs Saphris

FDA's Psychopharmacologic Drugs Advisory committee voted 12-0 that Saphris asenapine from Schering-Plough Corp. (NYSE:SGP) was safe and effective for acute treatment of manic or mixed episodes in adul...